跳到主要內容

臺灣博碩士論文加值系統

(44.210.151.5) 您好!臺灣時間:2024/07/13 10:20
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:陳靖瑛
研究生(外文):CHEN, CHIN-YIN
論文名稱:以智慧型手機服藥提醒APP探討思覺失調症病人之精神症狀、社會功能與生活品質
論文名稱(外文):Using App for medication adherence in patient with schizophrenia to improve psychotic symptoms, social function and quality of life
指導教授:謝秀芬謝秀芬引用關係
指導教授(外文):HSIEH, HSIU-FEN
口試委員:梁廷宇柯志鴻
口試委員(外文):LIANG, TYNG-YEUKO, CHIH-HUNG
口試日期:2022-06-28
學位類別:碩士
校院名稱:高雄醫學大學
系所名稱:護理學系碩士班
學門:醫藥衛生學門
學類:護理學類
論文種類:學術論文
論文出版年:2022
畢業學年度:110
語文別:中文
論文頁數:141
中文關鍵詞:思覺失調症手機應用程式服藥信守社會功能生活品質
外文關鍵詞:schizophreniaSmartphone Applicationmedication adherencesocial functionquality of lifeAPP(Application)
相關次數:
  • 被引用被引用:0
  • 點閱點閱:230
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
背景:思覺失調症的復發與藥物信守息息相關,根據研究顯示有高達 60%的思覺失調症病人有難配合服藥信守的問題,容易導致病情惡化 或者對抗精神病藥物產生耐受性,造成病情更難控制及困難治療,不僅有較高的疾病復發率,反覆發病容易造成病人認知功能受損,影響個人社會功能及生活品質,還會增加住院次數而提高醫療費用,造成家庭以及社會的負擔。在社區中的思覺失調症病人,有較高的復健潛能,規則服藥信守可以避免精神症狀惡化,減少個人認知及社會功能下降等問題。目前國內尚未見以智慧型手機應用程式改善思覺失調症個案服藥信守之相關研究。 目的:本研究以發展服藥APP應用程式提醒及維持病人服藥信守為主,期望服藥APP,能提升病人服藥信守、社會功能及其生活品質。 方法:本研究為類實驗性研究,在南部某二家醫學中心精神科日間留 院病房、社區復健中心,收集持有智慧型手機之思覺失調症個案,採用結構式量表包括簡易心智量表、正性與負性症狀評量表、圖像化個人與社會功能自我評估量表、台灣簡明版世界衛生組織生活問卷,進行資料收集,提供服藥APP後,以單組前、後測方式(one-group pre and pos-test design)共使用8週,分別在第0週、第8週進行測量評估差異。 結果:本研究共收案 25 人,發現 8 周期間病人服藥 APP 使用率達 80% 以上。另外手機服藥 APP 介入,思覺失調症病人 8 週後發現,精神症狀中的正性症狀(t 值:-3.823, p 值:0.001)與負性症狀(t 值:-2.296, p 值:0.033)、一般功能(t 值:-3.450, p 值:0.003)可達顯著差異。 社會功能、生活品質部分,沒有顯著差異。 討論:本研究發現使用服藥 APP 8 週後,可提升思覺失調症病人服藥達 8 成以上,不僅可以改善精神症狀中的正症狀,負性症狀、一般精神病理都得到改善,主要因為服藥 APP 是透過病人臉部與藥物辨識、提醒病人服藥、醫療聯盟群組交流、問卷系統、放鬆技巧、相關網站 連結等多元功能,也是過去研究未曾討論的部分;社會功能沒有顯著效果,可能因為社區思覺失調症病人主動性、現實感及執行功能以及自我照顧能力較優於急性病房病人,病情穩定不會有干擾及攻擊行為,且精神科社區是職業功能重建、提升社會功能為目標的半結構治療性環境,推論因此沒有顯著差異;參與本研究個案年齡低、高學歷、與家人同住、反覆住院率低,這些人口學特性與較佳的生活品質相關,病人對於自我能力理解與主觀生活品質可能與現實有落差,推論與本研究生活品質沒有顯著相關。
Background: Medication adherence is closely related to relapse of schizophrenia. According to research, up to 60% of schizophrenia patients have non-adherence with medication problem which may easily lead to deterioration or tolerance to antipsychotics, making the disease more difficult control and treatment . Therefore, patient with decline cognitive function and effect social function and quality of life. And also increase hospitalizations times and medical expenses, causing a burden on the family and society. Patients with schizophrenia in the community have a high potential for psychiatric rehabilitation, patient with good medication adherence to the prescribed medication can avoid the deterioration of mental symptoms and reduce problems such as the decline of personal and occupational functions. In view of the fact that many foreign studies have shown that reminding patients to take medicine through mobile phone APP has a significant effect on maintaining and stabilizing the patient's mental state and life function. At present, there is no relevant research for confirming medication adherence among patients with schizophrenia who use smartphone applications. Therefore, this study aims to develop a medication APP to remind and maintain patients' medication adherence. It is hoped that the additional functions of the mobile application can improve the Self- management of patients' medical treatment, reducing the workload of clinical medical staff, strengthening medical alliances, and looking forward to the added value of convenience in life through the functions of daily applications.
Methods: This study is a quasi-experimental study. Patient with schizophrenia who possess smartphones were collected in the psychiatric day care center and community rehabilitation center from two medical center in southern Taiwan. The medication APP setting was provided, which can be used in one-group pre and pos-test design. We measured the positive and negative symptom scale, self-reported graphic version of the personal and social performance scale, and the Taiwan abbreviated version of the World Health Organization Quality of Life Questionnaire after intervention 8 weeks later.
Results: A total of 25 cases were enrolled in this study. The data analysis was conducted when the usage rate reached more than 80% within 8 weeks. The results showed that the intervention of the mobile phone APP, the positive symptoms in the psychotic symptoms of schizophrenia patients (t:-3.823, p: 0.001) and negative symptoms (t: -2.296, p: 0.033) and general functioning (t: -3.450, p: 0.003) were significantly different. There was no significant difference in social function and quality of life.
Conclusions: We found that after 8 weeks of using the medication APP, it can increase the medication adherence of schizophrenia patients by more than 80%, which can not only improve the positive symptoms of mental symptoms, medication APP also improved the negative symptoms and general psychopathology. Multiple functions such as patient face and drug identification, reminding patients to take medication, medical alliance group communication, questionnaire system, relaxation techniques, and related website links are also parts that have not been discussed in previous studies; social functions have no significant effect, which may be due to community schizophrenia. The initiative, sense of reality, executive function and self- care ability of the patients with the disease are better than those of the patients in the acute ward, the condition is stable and there will be no interference and aggressive behavior, and the psychiatric community is a semi-structural therapeutic treatment with the goal of occupational function reconstruction and improvement of social function. Therefore, there is no significant difference in inferences due to different circumstances; the patients participating in this study were younger, highly educated, lived with family members, and had a low rate of repeated hospitalizations. These demographic characteristics were associated with better quality of life. The patients' understanding of self-ability and subjective quality of life may have a gap with reality, and the inference is not significantly related to the quality of life in this study.
第一章 緒論
第一節 問題背景及重要性 3
第二節 問題陳述 4
第三節 研究目的 5
第二章 文獻查證與研究架構
第一節 文獻查證-思覺失調症 10
第二節 思覺失調症與服藥信守之關係 13
第三節 思覺失調症服藥信守與精神症狀之關係 15
第四節 思覺失調症服藥信守與社會功能之關係 18
第五節 思覺失調症服藥信守與生活品質之關係 20
第六節 思覺失調症與行動醫療及智慧型手機應用程式 23
第七節 研究架構 25
第八節 研究假說 26
第九節 名詞定義 29
第三章 研究方法
第一節 研究設計 30
第二節 研究對象及樣本 32
第三節 研究工具 41
第四節 研究對象權益維護 43
第五節 資料蒐集過程 45
第六節 資料分析 46
第四章 研究結果
第一節 人口學基本資料之描述 50
第二節 精神症狀 54
第三節 社會功能 56
第四節 生活品質 58
第五章 討論
第一節 人口基本資料 59
第二節 服藥APP與思覺失調症之服藥信守 61
第三節 思覺失調症病人使用服藥 APP 與其精神症狀之關係 67
第四節 思覺失調症病人使用服藥APP與其社會功能之關係 71
第五節 思覺失調症病人使用服藥APP與其生活品質之關係 74
第六節 研究限制 77
第六章 結論與建議
第一節 綜合重要研究結果發現 79
第二節 在護理實務或教育上的意涵或應用 80
第三節 建議未來研究方向 81
第七章 參考文獻
中文部分 83
英文部分 105
圖一 研究架構圖 25
圖二 服藥 APP 主要功能架構圖示 34
圖三 服藥 APP 主要功能說明圖 37
圖四 資料搜集流程圖 45
表一 人口學基本資料之描述性統計 50
表二 使用服藥 APP 8 週後精神症狀之比較 52
表三 使用服藥 APP 8 週後正性與負性症狀評估量表之差異 54
表四 使用服藥 APP 8 週後社會功能之比較 56
表五 使用服藥 APP8 週後生活品質之比較 58
附件
附件一 研究工具
簡易心智量表 107
中文版正性與負性症狀評量表 108
圖像化之個人與社會功能自我評估量表 116
台灣簡明版世界衛生組織生活品質問卷 118
附件二 同意書
中文版正性與負性症狀表使用同意書 119
台灣簡明版世界維生組織生活品質問卷使用同意書 120
附件三 人體試驗委員會同意書
長庚醫療財團法人人體試驗倫理委員會研究同意書 127
高雄醫學大學附設中和紀念醫院人體研究新案同意證明書 128


中文參考文獻
台灣版世界衛生組織生活品質問卷發展小組(2000)。台灣版世界衛生組織生活品質問卷之發展簡介。中華公共衛生雜誌,19(4),315-324。https://doi.org/10.6288/cjph2000-19-04-10
國家發展委員會(2021)。110年身心障礙者數位發展現況與需求調查報告。臺北:國家發展委員會https://www.ndc.gov.tw/cp.aspx?n=55c8164714dfd9e9
黃任瑩、陳幸眉(2014)。慢性病患藥物治療信守之概念分析。護理雜誌,61(3),112-118。https://doi.org/10.6224/jn.61.3.112
蔣世光、花茂棽、陳震宇、平烈勇、趙建剛. (2016).。住院慢性思覺失調症病患臨床症狀因素結構和其剖面的探索性研究。中華心理學刊,58(1),1-18。https://doi.org/10.6129/cjp.20160308
鄭若瑟、何海、張景瑞、藍先元、胡海國 (1996)。活性與負性症狀量表(PANSS):中文版本建立及信度研究。中華精神醫學, 10,251–258. https://scholars.lib.ntu.edu.tw/handle/123456789/198953
陳美蘭、黃惠滿、高家常、楊燦(2013)。社區精神分裂病人病識感、服藥遵從行為及其相關因素之探討。高雄護理雜誌, 30(2),26-40。https://doi.org/10.6692/kjn-2013-30-2-3
郭乃文、劉秀枝、王珮芳、廖光淦、甄瑞興、林恭平、徐道昌 (1988)。「簡短式智能評估」之中文施測與常模建立。中華民 國復健醫學會雜誌(16), 52-59.
財團法人台灣網路資訊中心. (2019). 2019 台灣網路報告. 財團法人台灣網路資訊中心. https://report.twnic.tw/2019/
財團法人台灣網路資訊中心. (2020). 2020 台灣網路報告. 財團法人台灣網路資訊中心. https://report.twnic.tw/2020/
姚開屏(2002)。台灣版世界衛生組織生活品質問卷之發展與應用。 台灣醫學, 6(2), 193-200. https://doi.org/10.6320/fjm.2002.6(2).09
英文參考文獻
American Psychiatric Association. (2013). Diagnostic and statistical. manual of mental health. disorders (5th ed.).
Acosta, F. J., Hernandez, J. L., Pereira, J., Herrera, J., & Rodriguez, C. J. (2012). Medication adherence in schizophrenia. World J Psychiatry, 2(5), 74-82. https://doi.org/10.5498/wjp.v2.i5.74
Adery, L. H., Ichinose, M., Torregrossa, L. J., Wade, J., Nichols, H., Bekele, E., Park, S. (2018). The acceptability and feasibility of a novel virtual realty based social skills training game for schizophrenia: Preliminary findings. Psychiatry Res, 270, 496-502. https://doi.org/10.1016/j.psychres.2018.10.014
Andreasen, N. C., & Olsen, S. (1982). Negative v positive schizophrenia.Definition and validation. Arch Gen Psychiatry, 39(7), 789-794.
https://doi.org/10.1001/archpsyc.1982.04290070025006
Ascher-Svanum, H., Zhu, B., Faries, D. E., Salkever, D., Slade, E. P., Peng, X., & Conley, R. R. (2010). The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry, 10, 2. https://doi.org/10.1186/1471-244x-10-2
Badawy, S. M., Shah, R., Beg, U., & Heneghan, M. B. (2020). Habit.Strength, Medication Adherence, and Habit-Based Mobile Health Interventions Across Chronic Medical Conditions: Systematic Review. J Med Internet Res, 22(4), e17883. https://doi.org/10.2196/17883
Bai, Y. M., Hsiao, C. Y., Chen, K. C., Huang, K. L., Lee, I. H., Hsu, J. W., . . . Yang, Y. K. (2014). The development of a self-reported scale for measuring functionality in patients with schizophrenia--self- reported version of the graphic Personal and Social Performance (SRG-PSP) scale. Schizophr Res, 159(2-3), 546-551. https://doi.org/10.1016/j.schres.2014.08.024
Basit, S. A., Mathews, N., & Kunik, M. E. (2020). Telemedicine interventions for medication adherence in mental illness: A systematic review. Gen Hosp Psychiatry, 62, 28-36.https://doi.org/10.1016/j.genhosppsych.2019.11.004
Ben-Zeev, D., Brenner, C. J., Begale, M., Duffecy, J., Mohr, D. C., &. Mueser, K. T. (2014). Feasibility, acceptability, and preliminary efficacy of a smartphone intervention for schizophrenia. Schizophr Bull, 40(6), 1244-1253. https://doi.org/10.1093/schbul/sbu033
Ben-Zeev, D., Davis, K. E., Kaiser, S., Krzsos, I., & Drake, R. E. (2013).Mobile technologies among people with serious mental illness: opportunities for future services. Adm Policy Ment Health, 40(4), 340-343. https://doi.org/10.1007/s10488-012-0424-x
Ben-Zeev, D., Kaiser, S. M., Brenner, C. J., Begale, M., Duffecy, J., &. Mohr, D. C. (2013). Development and usability testing of FOCUS: a smartphone system for self-management of schizophrenia. Psychiatr Rehabil J, 36(4), 289-296. https://doi.org/10.1037/prj0000019
Ben-Zeev, D., Scherer, E. A., Gottlieb, J. D., Rotondi, A. J., Brunette, M. F., Achtyes, E. D., . . . Kane, J. M. (2016). mHealth for Schizophrenia: Patient Engagement With a Mobile Phone Intervention Following Hospital Discharge. JMIR Ment Health, 3(3), e34. https://doi.org/10.2196/mental.6348
Bohlken, J., Konrad, M., & Kostev, K. (2020). Adherence to neuroleptic. treatment in psychiatric practices: A retrospective study of 55 practices with more than 5000 bipolar and schizophrenic patients in Germany. Psychiatry Res, 284, 112758. https://doi.org/10.1016/j.psychres.2020.112758
Boyer, L., Millier, A., Perthame, E., Aballea, S., Auquier, P., & Toumi, M. (2013). Quality of life is predictive of relapse in schizophrenia. BMC Psychiatry, 13, 15. https://doi.org/10.1186/1471-244x-13-15
Charnsil, C., & Vongpanich, S. (2013). An open-label, prospective study to evaluate social function and overall improvement of extended-release paliperidone treatment in Thai schizophrenia patients. Neuropsychiatr Dis Treat, 9, 1223-1230. https://doi.org/10.2147/ndt.S47276
Chen, S. Y., Wen, F., Zhao, C. B., Zhang, D. M., & Wu, X. L. (2020).
Effect of cognitive impairment on social function and quality of life in chronic schizophrenia. Zhonghua Yi Xue Za Zhi, 100(5), 351-356. https://doi.org/10.3760/cma.j.issn.0376-2491.2020.05.007
Chivilgina, O., Wangmo, T., Elger, B. S., Heinrich, T., & Jotterand, F. (2020). mHealth for schizophrenia spectrum disorders management: A systematic review. Int J Soc Psychiatry, 66(7), 642-665. https://doi.org/10.1177/0020764020933287
Chue, P. (2006). The relationship between patient satisfaction and. treatment outcomes in schizophrenia. J Psychopharmacol, 20(6 Suppl), 38-56. https://doi.org/10.1177/1359786806071246
Desai, R., & Nayak, R. (2019). Effects of Medication Nonadherence and. Comorbidity on Health Resource Utilization in Schizophrenia. J Manag Care Spec Pharm, 25(1), 37-46.https://doi.org/10.18553/jmcp.2019.25.1.037
Desalegn, D., Girma, S., & Abdeta, T. (2020). Quality of life and its.
association with current substance use, medication non-adherence and clinical factors of people with schizophrenia in Southwest Ethiopia: a hospital-based cross-sectional study. Health Qual Life Outcomes, 18(1), 82. https://doi.org/10.1186/s12955-020-01340-0
Desalegn, D., Girma, S., & Abdeta, T. (2020). Quality of life and its.
association with current substance use, medication non-adherence and clinical factors of people with schizophrenia in Southwest Ethiopia: a hospital-based cross-sectional study. Health Qual Life Outcomes, 18(1), 82. https://doi.org/10.1186/s12955-020-01340-0
DiMatteo, M. R. (2004). Variations in patients' adherence to medical. recommendations: a quantitative review of 50 years of research. Med Care, 42(3), 200-209.https://doi.org/10.1097/01.mlr.0000114908.90348.f9
Dziwota, E., Stepulak, M. Z., Włoszczak-Szubzda, A., & Olajossy, M. (2018). Social functioning and the quality of life of patients diagnosed with schizophrenia. Ann Agric Environ Med, 25(1), 50-55. https://doi.org/10.5604/12321966.1233566
El Abdellati, K., De Picker, L., & Morrens, M. (2020). Antipsychotic. Treatment Failure: A Systematic Review on Risk Factors and Interventions for Treatment Adherence in Psychosis. Front Neurosci, 14, 531763. https://doi.org/10.3389/fnins.2020.531763
Ennis, L., Rose, D., Denis, M., Pandit, N., & Wykes, T. (2012). Can't surf,won't surf: the digital divide in mental health. J Ment Health, 21(4),
395-403. https://doi.org/10.3109/09638237.2012.689437
Firth, J., & Torous, J. (2015). Smartphone Apps for Schizophrenia: A.
Systematic Review. JMIR Mhealth Uhealth, 3(4), e102.
https://doi.org/10.2196/mhealth.4930
Fischer. B. A., &Buchanan ,R.W (2021) Schizophrenia in adults: Clinical
manifestations, course, assessment, and diagnosis. UpToDate. Retrieved March 16, 2022, from https://www.uptodate.com/contents/schizophrenia-in-adults-clinical- manifestations-course-assessment-and- diagnosis?search=schizophrenia%20treatment&topicRef=130944&so urce=see_link#H17284546
Flaherty, L. R., Daniels, K., Luther, J., Haas, G. L., & Kasckow, J. (2017). Reduction of medical hospitalizations in veterans with schizophrenia using home telehealth. Psychiatry Res, 255, 153-155. https://doi.org/10.1016/j.psychres.2017.05.024
Fox, S. (2011). Americans Living with Disability and Their Technology Profile. Pew Research Center.https://www.pewresearch.org/internet/2011/01/21/americans-living-
with-disability-and-their-technology-profile/
Fusar-Poli, P., Papanastasiou, E., Stahl, D., Rocchetti, M., Carpenter, W., Shergill, S., & McGuire, P. (2015). Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials. Schizophr Bull, 41(4), 892-899. https://doi.org/10.1093/schbul/sbu170
García, S., Martínez-Cengotitabengoa, M., López-Zurbano, S., Zorrilla, I., López, P., Vieta, E., & González-Pinto, A. (2016). Adherence to Antipsychotic Medication in Bipolar Disorder and Schizophrenic Patients: A Systematic Review. J Clin Psychopharmacol, 36(4), 355- 371. https://doi.org/10.1097/jcp.0000000000000523
Glick, I. D., Zamora, D., Davis, J. M., Suryadevara, U., Goldenson, A., &. Kamis, D. (2020). Are Patients With Schizophrenia Better Off With Lifetime Antipsychotic Medication?: Replication of a Naturalistic, Long-Term, Follow-Up Study of Antipsychotic Treatment. J Clin Psychopharmacol, 40(2), 145-148. https://doi.org/10.1097/jcp.0000000000001171
Gould, F., McGuire, L. S., Durand, D., Sabbag, S., Larrauri, C., Patterson,T. L., Harvey, P. D. (2015). Self-assessment in schizophrenia: Accuracy of evaluation of cognition and everyday functioning. Neuropsychology, 29(5), 675-682.
Granholm, E., Holden, J., Dwyer, K., Mikhael, T., Link, P., & Depp, C. (2020). Mobile-Assisted Cognitive Behavioral Therapy for Negative Symptoms: Open Single-Arm Trial With Schizophrenia Patients. JMIR Ment Health, 7(12), e24406. https://doi.org/10.2196/24406
Gupta, M., Bassett, E., Iftene, F., & Bowie, C. R. (2012). Functional. outcomes in schizophrenia: understanding the competence- performance discrepancy. J Psychiatr Res, 46(2), 205-211. https://doi.org/10.1016/j.jpsychires.2011.09.002
Hamine, S., Gerth-Guyette, E., Faulx, D., Green, B. B., & Ginsburg, A. S. (2015). Impact of mHealth chronic disease management on treatment adherence and patient outcomes: a systematic review. J Med Internet Res, 17(2), e52. https://doi.org/10.2196/jmir.3951
Harvey, P. D., & Bowie, C. R. (2012). Cognitive enhancement in. schizophrenia: pharmacological and cognitive remediation approaches. Psychiatr Clin North Am, 35(3), 683-698.https://doi.org/10.1016/j.psc.2012.06.008
Harvey, P. D., Deckler, E., Jones, M. T., Jarskog, L. F., Penn, D. L., &
Pinkham, A. E. (2019). Autism symptoms, depression, and active social avoidance in schizophrenia: Association with self-reports and informant assessments of everyday functioning. J Psychiatr Res, 115, 36-42. https://doi.org/10.1016/j.jpsychires.2019.05.010
Hasan, A. A. (2019). The correlation between the quality of life and. clinical variables among outpatients with schizophrenia. Psychiatry Res, 271, 39-45. https://doi.org/10.1016/j.psychres.2018.09.062
Higashi, K., Medic, G., Littlewood, K. J., Diez, T., Granstrom, O., & De. Hert, M. (2013). Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol, 3(4), 200- 218. https://doi.org/10.1177/2045125312474019
Kalin, M., Kaplan, S., Gould, F., Pinkham, A. E., Penn, D. L., & Harvey, P. D. (2015). Social cognition, social competence, negative symptoms and social outcomes: Inter-relationships in people with schizophrenia. J Psychiatr Res, 68, 254-260.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative. syndrome scale (PANSS) for schizophrenia. Schizophr Bull, 13(2), 261-276. https://doi.org/10.1093/schbul/13.2.261
Kemmler, G., Hummer, M., Widschwendter, C., & Fleischhacker, W. W. (2005). Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry, 62(12), 1305-1312.https://doi.org/10.1001/archpsyc.62.12.1305
Kidd, S. A., Feldcamp, L., Adler, A., Kaleis, L., Wang, W., Vichnevetski, K., . . . Voineskos, A. (2019). Feasibility and outcomes of a multi- function mobile health approach for the schizophrenia spectrum: App4Independence (A4i). PLoS One, 14(7), e0219491. https://doi.org/10.1371/journal.pone.0219491
Kirschner, M., Theodoridou, A., Fusar-Poli, P., Kaiser, S., & Jager, M. (2013). Patients' and clinicians' attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis. Ther Adv Psychopharmacol, 3(2), 89-99.
Kreyenbuhl, J., Record, E. J., Himelhoch, S., Charlotte, M., Palmer-Bacon,J., Dixon, L. B., . . . Li, L. (2019). Development and Feasibility Testing of a Smartphone Intervention to Improve Adherence to Antipsychotic Medications. Clin Schizophr Relat Psychoses, 12(4), 152-167. https://doi.org/10.3371/csrp.Krre.070816
Kreyenbuhl, J., Record, E. J., & Palmer-Bacon, J. (2016). A review of behavioral tailoring strategies for improving medication adherence in serious mental illness. Dialogues Clin Neurosci, 18(2), 191-201.
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002). Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry, 63(10), 892-909. https://doi.org/10.4088/jcp.v63n1007
Laursen, T. M., Munk-Olsen, T., & Vestergaard, M. (2012). Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry, 25(2), 83-88. https://doi.org/10.1097/YCO.0b013e32835035ca
Leucht, S., Kane, J. M., Kissling, W., Hamann, J., Etschel, E., & Engel, R. R. (2005). What does the PANSS mean? Schizophr Res, 79(2-3), 231- 238. https://doi.org/10.1016/j.schres.2005.04.008
Lysaker, P. H., Pattison, M. L., Leonhardt, B. L., Phelps, S., & Vohs, J. L. (2018). Insight in schizophrenia spectrum disorders: relationship with behavior, mood and perceived quality of life, underlying causes and emerging treatments. World Psychiatry, 17(1), 12-23. https://doi.org/10.1002/wps.20508
Marder, S. (2021). Psychosis in adults: Initial management. UpToDate. Retrieved March 17, 2022, from https://www.uptodate.com/contents/psychosis-in-adults-initial
management?sectionName=Antipsychotic%20therapy&search =schizophrenia%20treatment&topicRef=6962&anchor=H2504 773200&source=see_link#H2504773200
McCutcheon, R., Beck, K., D'Ambrosio, E., Donocik, J., Gobjila, C., Jauhar, S., Howes, O. D. (2018). Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatr Scand, 137(1), 39-46. https://doi.org/10.1111/acps.12825
McGrath, J., Saha, S., Chant, D., & Welham, J. (2008). Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev, 30, 67-76. https://doi.org/10.1093/epirev/mxn001
Misdrahi, D., Tessier, A., Husky, M., Lange, A. C., Vrijens, B., Llorca, P.M., & Bayle, F. J. (2018). Evaluation of adherence patterns in schizophrenia using electronic monitoring (MEMS(R)): A six-month post-discharge prospective study. Schizophr Res, 193, 114-118. https://doi.org/10.1016/j.schres.2017.06.026
Moritz, S., Favrod, J., Andreou, C., Morrison, A. P., Bohn, F., Veckenstedt, R., . . . Karow, A. (2013). Beyond the usual suspects: positive attitudes towards positive symptoms is associated with medication noncompliance in psychosis. Schizophr Bull, 39(4), 917-922. https://doi.org/10.1093/schbul/sbs005
Moritz, S., Hunsche, A., & Lincoln, T. M. (2014). Nonadherence to antipsychotics: the role of positive attitudes towards positive symptoms. Eur Neuropsychopharmacol, 24(11), 1745-1752. https://doi.org/10.1016/j.euroneuro.2014.09.008
Morosini, P. L., Magliano, L., Brambilla, L., Ugolini, S., & Pioli, R. (2000). Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand, 101(4), 323-329.
Möller, H. J. (2016). The Relevance of Negative Symptoms in Schizophrenia and How to Treat Them with Psychopharmaceuticals? Psychiatr Danub, 28(4), 435-440.
Murray, C. J. (1996). The global burden of disease. A comprehensive.assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020.
Nafees, B., van Hanswijck de Jonge, P., Stull, D., Pascoe, K., Price, M.,
Clarke, A., & Turkington, D. (2012). Reliability and validity of the Personal and Social Performance scale in patients with schizophrenia. Schizophr Res, 140(1-3), 71-76. https://doi.org/10.1016/j.schres.2012.06.013
Nasrallah, H., Morosini, P., & Gagnon, D. D. (2008). Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Res, 161(2), 213-224. https://doi.org/10.1016/j.psychres.2007.11.012
Nemoto, T., Uchino, T., Aikawa, S., Saito, J., Matsumoto, H., Funatogawa, T., . . . Mizuno, M. (2019). Social anxiety and negative symptoms as the characteristics of patients with schizophrenia who show competence-performance discrepancy in social functioning.Psychiatry Clin Neurosci, 73(7), 394-399.
https://doi.org/10.1111/pcn.12848
Osterberg, L., & Blaschke, T. (2005). Adherence to medication. N Engl J
Med, 353(5), 487-497. https://doi.org/10.1056/NEJMra050100
Phan, S. V. (2016). Medication adherence in patients with schizophrenia.
Int J Psychiatry Med, 51(2), 211-219.https://doi.org/10.1177/0091217416636601
Razali, S. M., & Yusoff, M. Z. (2014). Medication adherence in schizophrenia: a comparison between outpatients and relapse cases. East Asian Arch Psychiatry, 24(2), 68-74.
Robertson, B. R., Prestia, D., Twamley, E. W., Patterson, T. L., Bowie, C.
R., & Harvey, P. D. (2014). Social competence versus negative symptoms as predictors of real world social functioning in schizophrenia. Schizophr Res, 160(1-3), 136-141. https://doi.org/10.1016/j.schres.2014.10.037
Rus-Calafell, M., Gutiérrez-Maldonado, J., & Ribas-Sabaté, J. (2014). A virtual reality-integrated program for improving social skills in patients with schizophrenia: a pilot study. J Behav Ther Exp Psychiatry, 45(1), 81-89. https://doi.org/10.1016/j.jbtep.2013.09.002
Schulze, L. N., Stentzel, U., Leipert, J., Schulte, J., Langosch, J., Freyberger, H. J., . . . van den Berg, N. (2019). Improving Medication Adherence With Telemedicine for Adults With Severe Mental Illness. Psychiatr Serv, 70(3), 225-228. https://doi.org/10.1176/appi.ps.201800286
Semahegn, A., Torpey, K., Manu, A., Assefa, N., Tesfaye, G., & Ankomah, A. (2020). Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysis. Syst Rev, 9(1), 17. https://doi.org/10.1186/s13643-020-1274-3
Shadare, E. (2017). Increasing Medication Adherence and Compliance in Adults with Schizophrenia/Schizophrenia Spectrum Disorder (SSD) by using Mobile App Alarm Reminder for Medication Administration. Increasing Medication Adherence & Compliance in Adults with Schizophrenia/Schizophrenia Spectrum Disorder (SSD) by using Mobile App Alarm Reminder for Medication Administration, 1-1.
Stentzel, U., Grabe, H. J., Strobel, L., Penndorf, P., Langosch, J., Freyberger, H. J., . . . van den Berg, N. (2015). Tecla: a telephone and text-message based telemedical concept for patients with severe mental health disorders--study protocol for a controlled, randomized, study. BMC Psychiatry, 15, 273. https://doi.org/10.1186/s12888-015-0659-7
Stentzel, U., van den Berg, N., Moon, K., Schulze, L. N., Schulte, J., Langosch, J. M., . . . Grabe, H. J. (2021). Telemedical care and quality of life in patients with schizophrenia and bipolar disorder: results of a randomized controlled trial. BMC Psychiatry, 21(1), 318. https://doi.org/10.1186/s12888-021-03318-8
Stentzel, U., van den Berg, N., Schulze, L. N., Schwaneberg, T., Radicke, F., Langosch, J. M., . . . Grabe, H. J. (2018). Predictors of medication adherence among patients with severe psychiatric disorders: findings from the baseline assessment of a randomized controlled trial (Tecla). BMC Psychiatry, 18(1), 155. https://doi.org/10.1186/s12888-018-1737-4
Strassnig, M., Bowie, C., Pinkham, A. E., Penn, D., Twamley, E. W., Patterson, T. L., & Harvey, P. D. (2018). Which levels of cognitive impairments and negative symptoms are related to functional deficits in schizophrenia? J Psychiatr Res, 104, 124-129.https://doi.org/10.1016/j.jpsychires.2018.06.018
Stępnicki, P., Kondej, M., & Kaczor, A. A. (2018). Current Concepts and
Treatments of Schizophrenia. Molecules, 23(8). https://doi.org/10.3390/molecules23082087
Stroup,T. S, Marder, S. (2021). Schizophrenia in adults: Maintenance
therapy and. side effect management. Retrieved March 17, 2022, from https://www.uptodate.com/contents/schizophrenia-in-adults- maintenance-therapy-and-side-effect- management?search=Schizophrenia%20in%20adults:%20Maintena nce%20therapy%20and%20side%20effect%20management&source =search_result&selectedTitle=1~150&usage_type=default&display _rank=1
Terp, M., Jørgensen, R., Laursen, B. S., Mainz, J., & Bjørnes, C. D. (2018). A Smartphone App to Foster Power in the Everyday Management of Living With Schizophrenia: Qualitative Analysis of Young Adults' Perspectives. JMIR Ment Health, 5(4), e10157. https://doi.org/10.2196/10157
Tessier, A., Dupuy, M., Bayle, F. J., Herse, C., Lange, A. C., Vrijens, B., . . . Misdrahi, D. (2020). Brief interventions for improving adherence in schizophrenia: A pilot study using electronic medication event monitoring. Psychiatry Res, 112780. https://doi.org/10.1016/j.psychres.2020.112780
Tham, X. C., Xie, H., Chng, C. M. L., Seah, X. Y., Lopez, V., & Klainin- Yobas, P. (2018). Exploring predictors of medication adherence among inpatients with schizophrenia in Singapore's mental health settings: A non-experimental study. Arch Psychiatr Nurs, 32(4), 536-548. https://doi.org/10.1016/j.apnu.2018.02.004
Thomas, P., Mathur, P., Gottesman, II, Nagpal, R., Nimgaonkar, V. L., & Deshpande, S. N. (2007). Correlates of hallucinations in schizophrenia: A cross-cultural evaluation. Schizophr Res, 92(1-3), 41-49. https://doi.org/10.1016/j.schres.2007.01.017
Treisman, G. J., Jayaram, G., Margolis, R. L., Pearlson, G. D., Schmidt, C. W., Mihelish, G. L., . . . Misiuta, I. E. (2016). Perspectives on the Use of eHealth in the Management of Patients With Schizophrenia. J Nerv Ment Dis, 204(8), 620-629. https://doi.org/10.1097/nmd.0000000000000471
Turner, D. T., McGlanaghy, E., Cuijpers, P., van der Gaag, M., Karyotaki, E., & MacBeth, A. (2018). A Meta-Analysis of Social Skills Training and Related Interventions for Psychosis. Schizophr Bull, 44(3), 475-491. https://doi.org/10.1093/schbul/sbx146
Veerman, S. R. T., Schulte, P. F. J., & de Haan, L. (2017). Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review. Drugs, 77(13), 1423-1459. https://doi.org/10.1007/s40265-017- 0789-y
Vegt, J., & Guest, P. C. (2017). Development of a User-Friendly App for Testing Blood Coagulation Status in Schizophrenia Patients. Adv Exp Med Biol, 974, 351-360. https://doi.org/10.1007/978-3-319- 52479-5_34
Velthorst, E., Fett, A. J., Reichenberg, A., Perlman, G., van Os, J., Bromet, E. J., & Kotov, R. (2017). The 20-Year Longitudinal Trajectories of Social Functioning in Individuals With Psychotic Disorders. Am J Psychiatry, 174(11), 1075-1085. https://doi.org/10.1176/appi.ajp.2016.15111419
Wander, C. (2020). Schizophrenia: opportunities to improve outcomes and reduce economic burden through managed care. Am J Manag Care, 26(3 Suppl), S62-s68. https://doi.org/10.37765/ajmc.2020.43013
Wang, S. P., Wang, J. D., Chang, J. H., Wu, B. J., Wang, T. J., & Sun, H. J. (2020). Symptomatic remission affects employment outcomes in schizophrenia patients. BMC Psychiatry, 20(1), 219. https://doi.org/10.1186/s12888-020-02630-z
Wang, Y., Huang, Z., Xu, D., Gong, W., Tang, Y., & Xiao, S. (2016). [Strategies for measuring medication adherence in patients with schizophrenia]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 41(2), 218-224. https://doi.org/10.11817/j.issn.1672-7347.2016.02.016
World Health Organization. Adherence to Long Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003
Wu, B. J., Lin, C. H., Tseng, H. F., Liu, W. M., Chen, W. C., Huang, L. S., Lee, S. M. (2013). Validation of the Taiwanese Mandarin version of the Personal and Social Performance scale in a sample of 655 stable schizophrenic patients. Schizophr Res, 146(1-3), 34-39. https://doi.org/10.1016/j.schres.2013.01.036
Yu, Y., Li, Y., Li, T., Xi, S., Xiao, X., Xiao, S., & Tebes, J. K. (2020). New Path to Recovery and Well-Being: Cross-Sectional Study on WeChat Use and Endorsement of WeChat-Based mHealth Among People Living With Schizophrenia in China. J Med Internet Res,22(9), e18663. https://doi.org/10.2196/18663




電子全文 電子全文(網際網路公開日期:20270719)
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
無相關期刊